Corvus Pharmaceuticals, Inc. — Director's Dealing 2022

Mar 17, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Corvus Pharmaceuticals, Inc. (CRVS)
CIK: 0001626971
Period of Report: 2022-03-16

Reporting Person: LEA LEIV (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-16	Common Stock	P	35160	$1.54	Acquired	85360	Indirect
2022-03-17	Common Stock	P	13878	$1.65	Acquired	99238	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	149206	Indirect

Footnotes

F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.45 to $1.60 inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2: These shares are held by Leiv Lea IRA Contributory.

F3: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.62 to $1.66 inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F4: These shares are held by Leiv Lea and Deborah Karlson, Trustees of the Karlson Lea Family Trust UTA dated February 11, 1998 (the "Karlson Lea Trust"). Mr. Lea has shared voting, investment and dispositive power over the shares held by the Karlson Lea Trust.